Bioequivalence assessment of imeglimin hydrochloride tablet, a novel glimin-class antidiabetic agent.

PURPOSE: While imeglimin's, oral antidiabetic agent, efficacy and safety are established in Japanese and Western populations, pharmacokinetic data from Middle Eastern and African cohorts remain limited. This study aimed to evaluate the bioequivalence…

Preview only. Read the full abstract at the source